[
  {
    "ts": null,
    "headline": "Abbott (ABT) Stock Moves -0.15%: What You Should Know",
    "summary": "In the closing of the recent trading day, Abbott (ABT) stood at $131.30, denoting a -0.15% change from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=d3248c50d034b7d726d1ea9747b94dbc229f4b25be2f443b451fab01423050e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748037004,
      "headline": "Abbott (ABT) Stock Moves -0.15%: What You Should Know",
      "id": 134685753,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Abbott (ABT) stood at $131.30, denoting a -0.15% change from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=d3248c50d034b7d726d1ea9747b94dbc229f4b25be2f443b451fab01423050e1"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (NYSE:ABT) Collaborates On Advanced Diabetes Management With Glucose-Ketone Sensor Integration",
    "summary": "Abbott Laboratories (NYSE:ABT) made headlines with its commercial development agreement to integrate advanced diabetes management technology with Sequel Med Tech, aiming to improve outcomes for individuals with type 1 diabetes. Over the past month, Abbott's on-market total shareholder returns remained flat, reflecting broader market trends influenced by ongoing global trade tensions. Despite the market's 1.4% decline during the same period, Abbott's announcements, including partnerships and...",
    "url": "https://finnhub.io/api/news?id=0a2ac6bd0489ef6155b480e8fdbe0a5296fc20899466154bc46a4f2459457c5e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748021753,
      "headline": "Abbott Laboratories (NYSE:ABT) Collaborates On Advanced Diabetes Management With Glucose-Ketone Sensor Integration",
      "id": 134685754,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) made headlines with its commercial development agreement to integrate advanced diabetes management technology with Sequel Med Tech, aiming to improve outcomes for individuals with type 1 diabetes. Over the past month, Abbott's on-market total shareholder returns remained flat, reflecting broader market trends influenced by ongoing global trade tensions. Despite the market's 1.4% decline during the same period, Abbott's announcements, including partnerships and...",
      "url": "https://finnhub.io/api/news?id=0a2ac6bd0489ef6155b480e8fdbe0a5296fc20899466154bc46a4f2459457c5e"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) was up 16% in Q1",
    "summary": "Polen Capital, an investment management company, released its “Polen Global Growth Strategy” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equity markets experienced a surge in volatility in 2025 due to US tariffs, with the “Magnificent 7” falling 15% and semiconductors dropping 19%. U.S. stocks lagged, with international equities […]",
    "url": "https://finnhub.io/api/news?id=3e6ea221f472dbaf2a7e97ca029e631379ba9e0d6ce225400e51957ad9891ad0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748012943,
      "headline": "Abbott Laboratories (ABT) was up 16% in Q1",
      "id": 134685755,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Polen Capital, an investment management company, released its “Polen Global Growth Strategy” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equity markets experienced a surge in volatility in 2025 due to US tariffs, with the “Magnificent 7” falling 15% and semiconductors dropping 19%. U.S. stocks lagged, with international equities […]",
      "url": "https://finnhub.io/api/news?id=3e6ea221f472dbaf2a7e97ca029e631379ba9e0d6ce225400e51957ad9891ad0"
    }
  },
  {
    "ts": null,
    "headline": "Was Jim Cramer Right About Abbott Laboratories (ABT)?",
    "summary": "We recently published a list of Jim Cramer Nailed These 11 Stock Predictions. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks that Jim Cramer discusses. Back in 2024, on May 20, a caller asked whether to hold or buy more shares of Abbott Laboratories […]",
    "url": "https://finnhub.io/api/news?id=748b6ace7f7ec37c5e59e269d760a20b4c5cc1ff6d2229cad6797029c1db35aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748000906,
      "headline": "Was Jim Cramer Right About Abbott Laboratories (ABT)?",
      "id": 134658518,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Nailed These 11 Stock Predictions. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks that Jim Cramer discusses. Back in 2024, on May 20, a caller asked whether to hold or buy more shares of Abbott Laboratories […]",
      "url": "https://finnhub.io/api/news?id=748b6ace7f7ec37c5e59e269d760a20b4c5cc1ff6d2229cad6797029c1db35aa"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Stocks to Buy With $500 and Hold Forever",
    "summary": "Zoetis is a leading animal health company with a deep lineup and significant long-term tailwinds.  Abbott Labs has a diversified portfolio of medical devices and several attractive growth avenues.  The fact that the stock market will sometimes go through erratic periods is not a good reason not to invest.",
    "url": "https://finnhub.io/api/news?id=7caf38005765cd957899e797f15f09d64d8cd1589798a212986194b1a4b2e097",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747996200,
      "headline": "2 Dividend Stocks to Buy With $500 and Hold Forever",
      "id": 134658519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Zoetis is a leading animal health company with a deep lineup and significant long-term tailwinds.  Abbott Labs has a diversified portfolio of medical devices and several attractive growth avenues.  The fact that the stock market will sometimes go through erratic periods is not a good reason not to invest.",
      "url": "https://finnhub.io/api/news?id=7caf38005765cd957899e797f15f09d64d8cd1589798a212986194b1a4b2e097"
    }
  }
]